Deanna J. Brackman

856 total citations · 1 hit paper
18 papers, 524 citations indexed

About

Deanna J. Brackman is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Deanna J. Brackman has authored 18 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Deanna J. Brackman's work include Acute Myeloid Leukemia Research (4 papers), Drug Transport and Resistance Mechanisms (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Deanna J. Brackman is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Drug Transport and Resistance Mechanisms (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Deanna J. Brackman collaborates with scholars based in United States, Germany and Japan. Deanna J. Brackman's co-authors include Kathleen M. Giacomini, Sook Wah Yee, Eric M. Bachelder, Kevin J. Peine, Kristy M. Ainslie, Landry K. Kamdem, Yuichi Sugiyama, E Ennis, Rebecca Blanchard and Aleksandra Galetin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Langmuir.

In The Last Decade

Deanna J. Brackman

18 papers receiving 515 citations

Hit Papers

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Re... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    2022 123 citations Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology profile →

Peers

Deanna J. Brackman
Alan Fotoohi Sweden
Lisa M. Chelstrom United States
Rafael Ríos Spain
Myung S. Rhee United States
Michelle Horner United States
Ralf Häfer Germany
John Bognacki United States
Wenrong Huang China
A Ueki Japan
Anthony J. Chubb Ireland
Alan Fotoohi Sweden
Deanna J. Brackman
Citations per year, relative to Deanna J. Brackman Deanna J. Brackman (= 1×) peers Alan Fotoohi

Countries citing papers authored by Deanna J. Brackman

Since Specialization
Citations

This map shows the geographic impact of Deanna J. Brackman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deanna J. Brackman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deanna J. Brackman more than expected).

Fields of papers citing papers by Deanna J. Brackman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deanna J. Brackman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deanna J. Brackman. The network helps show where Deanna J. Brackman may publish in the future.

Co-authorship network of co-authors of Deanna J. Brackman

This figure shows the co-authorship network connecting the top 25 collaborators of Deanna J. Brackman. A scholar is included among the top collaborators of Deanna J. Brackman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deanna J. Brackman. Deanna J. Brackman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Jonas, Brian A., Jing‐Zhou Hou, Gail J. Roboz, et al.. (2023). A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology. 41(4). 743–752. 12 indexed citations
2.
Mascarenhas, John, Lei He, Nashat Gabrail, et al.. (2023). PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY. HemaSphere. 7(S3). e8258903–e8258903. 1 indexed citations
3.
Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059. 123 indexed citations breakdown →
4.
Mukherjee, Dwaipayan, Deanna J. Brackman, Ahmed A. Suleiman, et al.. (2022). Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK‐Informed Analysis. The Journal of Clinical Pharmacology. 63(1). 119–125. 8 indexed citations
5.
Brackman, Deanna J., Rajeev Menon, Ahmed Hamed Salem, et al.. (2022). Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematological Oncology. 40(2). 269–279. 24 indexed citations
6.
7.
Vora, Bianca, Deanna J. Brackman, Ling Zou, et al.. (2021). Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. Clinical and Translational Science. 14(4). 1431–1443. 12 indexed citations
8.
9.
Brackman, Deanna J., Rajeev Menon, Ahmed Hamed Salem, et al.. (2020). Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. Blood. 136(Supplement 1). 52–52. 1 indexed citations
10.
Lang, Sven, Tyler Hilsabeck, Kenneth A. Wilson, et al.. (2019). A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster. PLoS Genetics. 15(8). e1008318–e1008318. 39 indexed citations
11.
Brackman, Deanna J., Sook Wah Yee, Christian M. Shaffer, et al.. (2019). Genome‐Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clinical Pharmacology & Therapeutics. 106(3). 623–631. 22 indexed citations
12.
Yee, Sook Wah, Deanna J. Brackman, E Ennis, et al.. (2018). Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. Clinical Pharmacology & Therapeutics. 104(5). 803–817. 98 indexed citations
13.
Fohner, Alison E., Deanna J. Brackman, Kathleen M. Giacomini, Russ B. Altman, & Teri E. Klein. (2017). PharmGKB summary. Pharmacogenetics and Genomics. 27(11). 420–427. 25 indexed citations
14.
Brackman, Deanna J. & Kathleen M. Giacomini. (2017). Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response. Clinical Pharmacology & Therapeutics. 103(2). 233–242. 22 indexed citations
15.
Peine, Kevin J., Eric M. Bachelder, Zachary VanGundy, et al.. (2013). Efficient Delivery of the Toll-like Receptor Agonists Polyinosinic:Polycytidylic Acid and CpG to Macrophages by Acetalated Dextran Microparticles. Molecular Pharmaceutics. 10(8). 2849–2857. 50 indexed citations
16.
Peine, Kevin J., Gaurav Gupta, Deanna J. Brackman, et al.. (2013). Liposomal resiquimod for the treatment of Leishmania donovani infection. Journal of Antimicrobial Chemotherapy. 69(1). 168–175. 32 indexed citations
17.
Gallovic, Matthew D., Sadhana Sharma, Kevin J. Peine, et al.. (2013). Electrospun Acetalated Dextran Scaffolds for Temporal Release of Therapeutics. Langmuir. 29(25). 7957–7965. 29 indexed citations
18.
Bourrillon, A, et al.. (1984). Cefotaxime Effects on the Intestinal Flora of the Newborn. Developmental Pharmacology and Therapeutics. 7(S1). 144–149. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alan Fotoohi Breakdown of academic impact, for papers by Lisa M. Chelstrom Breakdown of academic impact, for papers by Rafael Ríos Breakdown of academic impact, for papers by Myung S. Rhee Breakdown of academic impact, for papers by Michelle Horner Breakdown of academic impact, for papers by Ralf Häfer Breakdown of academic impact, for papers by John Bognacki Breakdown of academic impact, for papers by Wenrong Huang Breakdown of academic impact, for papers by A Ueki Breakdown of academic impact, for papers by Anthony J. Chubb
Rankless by CCL
2026